Paper Details

  1. Home
  2. Paper Details

Systemic safety of anti-VEGF drugs: a commentary.

Author: ChakravarthyUsha, ReevesBarnaby C, RogersChris A, ScottLauren J

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This research addresses concerns regarding the use of VEGF inhibitors for treating neovascular age-related macular degeneration (nAMD). The study examines the use of ranibizumab, aflibercept, and bevacizumab, VEGF inhibitors that have been licensed or used off-label for nAMD, exploring the potential risks and benefits of these therapies.
Paper Details　
Original Abstract of the Article :
VEGF is a mediator of angiogenesis. Thus, concerns have been expressed following the use of VEGF inhibitors for the treatment of neovascular age-related macular degeneration (nAMD). Ranibizumab, and more recently aflibercept, are VEGF inhibitors licensed for the treatment of nAMD. Bevacizumab is als...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2015.991712

データ提供：米国国立医学図書館（NLM）

Anti-VEGF Drugs: Balancing Benefits and Risks

The field of [neovascular age-related macular degeneration (nAMD)] treatment has seen significant advancements with the development of anti-vascular endothelial growth factor (VEGF) drugs. This commentary discusses the systemic safety of anti-VEGF drugs, highlighting the concerns and considerations associated with their use.

Anti-VEGF Drugs: A Double-Edged Sword

The commentary acknowledges the effectiveness of anti-VEGF drugs in treating nAMD but also highlights concerns regarding potential systemic side effects. While these drugs have proven beneficial for ophthalmic conditions, their potential impact on other systems raises important questions about their long-term safety and the need for ongoing monitoring and research.

Navigating the Risks and Rewards of New Therapies

The development of new therapies often brings with it both promise and potential risks. It's essential to carefully evaluate the benefits and risks of any treatment, especially when considering long-term use. This commentary underscores the importance of ongoing research to understand the long-term effects of anti-VEGF drugs and ensure patient safety. Just as a camel must be cautious in the desert environment, healthcare professionals must proceed with caution when introducing new therapies and closely monitor patient responses.

Dr.Camel's Conclusion

The commentary highlights the importance of ongoing research and careful consideration of potential risks when using anti-VEGF drugs. As a camel who has witnessed the transformative power of scientific advancements, I am always mindful of the need to balance progress with caution. The field of medicine must continue to strive for innovative therapies while ensuring patient safety and well-being.

Date :
  1. Date Completed 2015-09-28
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

25489638

DOI: Digital Object Identifier

10.1517/14740338.2015.991712

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.